CoChat

Harnessing T cells to fight cancer with BiTE® antibody constructs – past developments and future directions

Klinger, Matthias, Benjamin, Jonathan, Kischel, Roman, Stienen, Sabine, Zugmaier, Gerhard · 2016 · Immunological Reviews
Cited by 156

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Summary: Bispecific T‐cell engager (Bi TE®) antibody constructs represent a novel immunotherapy that bridges cytotoxic T cells to tumor cells, thereby inducing target cell‐dependent polyclonal T‐cell activation and proliferation, and leading to apoptosis of bound tumor cells. Anti‐CD 19 Bi TE® blinatumomab has demonstrated clinical activity in Philadelphia chromosome (Ph)‐negative relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) eventually resulting in conditional approval by the U.S. Food and Drug Administration in 2014. This drug is currently further developed in pediatric and Ph+ r/r, as well as in minimal residual disease‐positive ALL, and might also offer clinical benefit for patients with non‐Hodgkin's lymphoma, especially for those with aggressive forms like diffuse large B‐cell lymphoma. Another Bi TE® antibody construct in hemato‐oncology designated AMG 330 targets CD 33 on acute myeloid leukemia blast cells. After showing promising ex vivo activity, this drug candidate has recently entered phase 1 clinical development, and has further indicated potential for combination with checkpoint inhibitors. In solid tumor indications, three Bi TE® antibody constructs have been tested in phase 1 studies so far: anti‐Ep CAM Bi TE® AMG 110, anti‐CEA Bi TE® MEDI‐565/AMG 211, and anti‐PSMA Bi TE® BAY 2010112/AMG 212. Pertinent questions comprise how to maximize Bi TE® penetration and T‐cell infiltration of the tumor while simultaneously minimizing any adverse events, which is currently explored by a continuous intravenous infusion approach. Thus, Bi TE® antibody constructs will hopefully provide new treatment options for patients in several indications with high unmet medical need.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/imr.12393

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 156

Metadata

Authors
Klinger, M., Benjamin, J., Kischel, R., Stienen, S., & Zugmaier, G.
Venue
Immunological Reviews
Publisher
Wiley
Published
2016-02-10
Volume
270
Issue
1
Pages
193-208
ISSN
  • 0105-2896 (ISSN-L)
  • 1600-065X
OpenAlex
W2278340539
Cited by
156
References
18
FWCI
2.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.